Abgenix to become sole owner of Xenomouse fully human antibody technology

Contact: Kurt Leutzinger Vice President and Chief Financial Officer Abgenix Inc. (510) 608-6575 or Marion E. Glick Porter Novelli 212/601-8273 ABGENIX TO BECOME SOLE OWNER OF XENOMOUSE FULLY HUMAN ANTIBODY TECHNOLOGY -Abgenix to Acquire Japan Tobacco's Interests in Xenotech Joint Venture - FREMONT, CALIFORNIA - December 20, 1999 - Abgenix, Inc. (Nasdaq: ABGX) will become the sole owner of the XenoMouse, a leading technology for generating fully human antibody drugs useful in treating a wide range of diseases, by acquiring all of the interest in the technology owned by JT America Inc. (JT America). Under the agreements signed today, Abgenix will pay $47 million to JT America for its 50 percent interest in Xenotech, Inc., and Xenotech, L.P., (Xenotech), an equally owned limited partnership between the two companies that created the XenoMouse. Abgenix will also pay $10 million as compensation to Japan Tobacco, Inc. (JT) to relinquish certain option and license rights it is currently entitled to. The acquisition, expected to close by year-end, is contingent upon approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. "Abgenix's acquisition of Japan Tobacco's share of the Xenotech partnership reflects our profound enthusiasm for the commercial potential of the XenoMouse technology," stated R. Scott Greer, president and CEO of Abgenix. "With sole ownership of this industry-leading technology, we will capture 100 percent of the value of the XenoMouse technology deals executed to date as well as remove limits on the number and form of deals Abgenix can do in the future. For example, our recently completed multi-product alliances with two leading genomics companies, Human Genome Sciences and CuraGen, will be facilitated by this transaction." Under the arrangement, JT will have a research license to use XenoMouse technology and options to license the technology for a small number of antigen targets each year. Abgenix also will

Contact: Kurt Leutzinger, Abgenix, Inc.
Porter Novelli

Page: 1 2 3 4

Related biology news :

1. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
2. Abgenix initiates phase III clinical trial of graft versus host disease therapy
3. Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
4. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
5. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. $18 million bioinformatics center to become weapon against deadly diseases
8. Biochemist becomes 15th UT Southwestern faculty member serving on National Academy of Sciences
9. Brain cells become more discriminating when they work together
10. How meals become bones
11. Adult mouse bone marrow stem cells can become cells of the nervous system

Post Your Comments:

(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: